EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Overview of clinical, molecular, and therapeutic features of Niemann–Pick disease (types A, B, and C): Focus on therapeutic approaches

Kamran Hosseini, Jafar Fallahi, Vahid Razban, Reyhaneh Zayyani Sirat, Mahnaz Varasteh, Vahideh Tarhriz

Cell Biochemistry and Function · 2024-06 · 42 (4)

DOI: 10.1002/cbf.4028 ↗

At a glance

Übersichtsarbeit in Cell Biochemistry and Function, published online on 2024-05-07. Written by Kamran Hosseini and 5 co-authors. Institution: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Major MEDLINE topics: Genetic Therapy, Mutation, Niemann-Pick C1 Protein. Cited 14 times so far (Crossref); 156 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Niemann–Pick disease (NPD) is another type of metabolic disorder that is classified as lysosomal storage diseases (LSDs). The main cause of the disease is mutation in the SMPD1 (type A and B) or NPC1 or NPC2 (type C) genes, which lead to the accumulation of lipid substrates in the lysosomes of the liver, brain, spleen, lung, and bone marrow cells. This is followed by multiple cell damage, dysfunction of lysosomes, and finally dysfunction of body organs. So far, about 346, 575, and 30 mutations have been reported in SMPD1 , NPC1 , and NPC2 genes, respectively. Depending on the type of mutation and the clinical symptoms of the disease, the treatment will be different. The general aim of the current study is to review the clinical and molecular characteristics of patients with NPD and study various treatment methods for this disease with a focus on gene therapy approaches.

Subjects

MeSH terms (MEDLINE)

Genetic TherapyMutationNiemann-Pick C1 ProteinHumansIntracellular Signaling Peptides and ProteinsNiemann-Pick Disease, Type CNiemann-Pick DiseasesSphingomyelin PhosphodiesteraseVesicular Transport Proteins

Author keywords

NPCNiemann–Pick diseasegene therapylysosomal storage diseasesmetabolic disorder

Substances

Intracellular Signaling Peptides and ProteinsNiemann-Pick C1 ProteinNPC1 protein, humanNPC2 protein, humanSMPD1 protein, humanSphingomyelin PhosphodiesteraseVesicular Transport Proteins

Authors and institutions

  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Molecular Medicine, Faculty of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Zand Institute of Higher Education, Shiraz, Iran.
  • Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.

Cite

APA

Hosseini, K., Fallahi, J., Razban, V., Sirat, R. Z., Varasteh, M., & Tarhriz, V. (2024). Overview of clinical, molecular, and therapeutic features of Niemann–Pick disease (types A, B, and C): Focus on therapeutic approaches. Cell Biochemistry and Function, 42(4). https://doi.org/10.1002/cbf.4028

Vancouver

Hosseini K, Fallahi J, Razban V, Sirat RZ, Varasteh M, Tarhriz V. Overview of clinical, molecular, and therapeutic features of Niemann–Pick disease (types A, B, and C): Focus on therapeutic approaches. Cell Biochemistry and Function. 2024;42(4). doi:10.1002/cbf.4028

BibTeX
@article{Hosseini2024,
  author = {Hosseini, Kamran and Fallahi, Jafar and Razban, Vahid and Sirat, Reyhaneh Zayyani and Varasteh, Mahnaz and Tarhriz, Vahideh},
  title = {Overview of clinical, molecular, and therapeutic features of Niemann–Pick disease (types A, B, and C): Focus on therapeutic approaches},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  volume = {42},
  number = {4},
  doi = {10.1002/cbf.4028}
}
Start for free →